Gestational GLP-1s Tied to Adverse Obstetric Outcomes
A study has found that mothers with overweight or obesity who used semaglutide during pregnancy faced higher risks of adverse outcomes. These include excessive gestational weight gain, gestational diabetes, and cesarean delivery. The findings highlight the need for further research on the implications of GLP-1 use in pregnancy and its effects on long-term child health.
- ▪Mothers exposed to semaglutide had a 5.12-kg greater gestational weight gain compared to nonusers.
- ▪The study reported higher risks for gestational diabetes and excessive fetal growth among semaglutide users.
- ▪About a third of women on semaglutide before pregnancy continued its use after conception.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/periconceptional-gestational-semaglutide-tied-adverse-2026a1000ih1?src=rss |
| Publication time | Wed, 3 Jun 2026 09:06:33 EDT |
| Retrieval time | 2026-06-03T13:12:07.669Z |
| Last seen | 2026-06-03T13:12:07.669Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 5VvX9sbrC9fO |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Mothers with overweight or obesity exposed to semaglutide before and during pregnancy had higher risks for excessive gestational weight gain, gestational diabetes, excessive fetal growth, and cesarean delivery than nonusers, a national database study in Obstetrics and Gynecology found.Yang Yu, PhD, MPH, MNSStudy investigators led by Yang Yu, PhD, MPH, MNS, an assistant professor at the University of Rochester School of Nursing in Rochester, New York, noted that current drug labeling advises discontinuing the drug at least 2 months before attempting to conceive, a warning based on animal research linking use in pregnancy to miscarriage, impaired fetal growth, and congenital anomalies.However, unintended exposure during pregnancy is likely common, given the growth of GLP-1 use in…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
